[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Fourth Affiliated Hospital of China Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100619029","a-novel-fluorescent-ductal-needle-for-localization-and-sampling-of-micro-lesions-in-breast-ducts-100619029",false,"NCT07339306","A Novel Fluorescent Ductal Needle for Localization and Sampling of Micro Lesions in Breast Ducts","A Novel Fluorescent Ductal Needle With Controllable Detachment for Realtime Localization and Sampling of Micro Lesions in Breast Ducts: a Prospective, Multicenter Study","Inclusion Criteria:\n\n1. Female patients aged 18-75 years.\n2. Patients scheduled to undergo duct excision surgery.\n3. Patients who are capable of providing written informed consent and adhering to the study protocols.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding.\n2. Patients who have known allergy to quantum-dot materials or localization needle components.\n3. Patients with active hepatitis B or C infection with detectable viral load.\n4. Patients with unstable cardiovascular disease (e.g., recent myocardial infarction, uncontrolled arrhythmia, NYHA class III-IV heart failure).\n5. Patients with history of neurological or psychiatric disorders that may impair compliance (e.g., epilepsy, dementia).\n6. Patients who concurrent participation in another interventional clinical trial.","FEMALE","18 Years","75 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective, multicenter cohort study investigates the differences in the reliability of rapid pathology compared to postoperative pathology when utilizing a novel fluorescent localization needle equipped with a controllable shedding quantum dot chiral nanofluorescent coating, in contrast to traditional localization techniques for breast duct lesions. The principal objective is to assess the clinical efficacy of this innovative fluorescent localization needle in enabling precise pathological diagnosis of micro lesions in breast ducts.",[27,28,29],"Mammary Tumor","Nipple Discharge","Breast Ductal Carcinoma In Situ",[31,32,33,34,35],"micro lesions","breast duct","fluorescent ductal needle","localization needle","controllable detachment","RECRUITING","2026-06-10",{"date":39,"type":40},"2026-06-11","ACTUAL",{"date":42,"type":40},"2026-01-01",{"date":44,"type":21},"2026-09-30",{"name":46,"class":47},"The Fourth Affiliated Hospital of China Medical University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":56,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":48},"100592514","a-novel-fluorescent-ductal-needle-for-localization-and-sampling-of-high-risk-breast-micro-lesions-100592514","NCT06994416","A Novel Fluorescent Ductal Needle for Localization and Sampling of High-risk Breast Micro Lesions","A Novel Fluorescent Ductal Needle With Controllable Detachment for Real-time Localization and Sampling of High-risk Breast Micro Lesions: a Retrospective Study","Inclusion Criteria:\n\n1. Female patients aged 18-75 years.\n2. Patients who have been diagnosed intraductal breast lesion by ductoscopy.\n3. Patients who have undergone ductal excision.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding.\n2. Patients who have known allergy to quantum-dot materials or localization needle components.\n3. Patients with active hepatitis B or C infection with detectable viral load.\n4. Patients with unstable cardiovascular disease (e.g., recent myocardial infarction, uncontrolled arrhythmia, NYHA class III-IV heart failure).\n5. Patients with history of neurological or psychiatric disorders that may impair compliance (e.g., epilepsy, dementia).\n6. Patients with incomplete clinical data.\n7. Patients who concurrent participation in another interventional clinical trial.",{"count":20,"type":21},"OBSERVATIONAL","This retrospective cohort study investigates the differences in the reliability of rapid pathology compared to postoperative pathology when utilizing a novel fluorescent localization needle equipped with a controllable shedding quantum dot chiral nanofluorescent coating, in contrast to traditional localization techniques for breast duct lesions. The primary goal is to evaluate the clinical effectiveness of this innovative fluorescent localization needle in facilitating accurate pathological diagnoses of micro lesions situated within breast ducts.",[27,28],[31,32,33,34,35],{"date":39,"type":40},{"date":63,"type":40},"2025-06-01",{"date":65,"type":21},"2026-05-31",{"name":46,"class":47},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":73,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":48},"100539279","a-prospective-experimental-multicenter-open-label-randomized-controlled-trial-of-3-month-dual-antiplatelet-therapy-followed-by-ticagrelor-versus-6-month-dual-antiplatelet-therapy-followed-by-ticagrelor-after-implanting-bridge-100539279","NCT06301776","A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge","Inclusion Criteria:\n\n* Patients who are suitable for Bridge implantation\n* Symptomatic vertebral artery stenosis with a history of posterior circulation-related ischaemic stroke or TIA despite the use of at least one antithrombotic medications and intervention for risk factors\n* Responsible vertebral artery stenosis (≥70% stenosis, measured by the NASCET method ) confirmed by DSA imaging\n* The patient and\u002For his\u002Fher authorised person understands the purpose of the study, agrees to participate in the study and signs the informed consent form\n\nExclusion Criteria:\n\n* mRS≥3\n* Presence of tandem stenotic lesions in the target lesion areaor combined basilar artery stenosis Presence of ≥2 stenotic cerebrovascular lesions requiring concurrent intervention The presence of severe tortuosity or calcification of the target vessel, or the presence of extensive abnormal vascular structural variants that are difficult for catheters or stents to pass or cannot be implanted\n* Lesions or stenosis that is too large and beyond the specification of the stent\n* Non-atherosclerotic stenosis such as atrial fibrillation, vasculitis stenosis, arterial entrapment, smoky disease, active phase of arteritis, or unknown cause\n* Contraindication to heparin, aspirin, tegretol, clopidogrel, or other antiplatelet drugs, and those who cannot tolerate anticoagulant and antiplatelet drug therapy\n* Have had intracranial haemorrhage within 3 months\n* Had a myocardial infarction or large cerebral infarction within 2 weeks\n* Accompanied by other intracranial disease such as aneurysm, arteriovenous malformation, intracranial tumour, intracranial infection, etc\n* Presence of active bleeding or extremely dangerous risk of haemorrhage (e.g. active peptic ulcer disease, gastrointestinal lesions with bleeding risk, malignant tumours with bleeding risk, etc.)\n* Severe cardiac, hepatic, splenic, pulmonary, or renal impairment, or allergy or intolerance to contrast media, rapamycin (Rapamycin) and its derivatives, cobalt-based alloys, or polylactic acid","ALL","80 Years",{"count":76,"type":21},560,[24],"To compare the incidence of the composite endpoints of non-fatal ischaemic stroke, transient ischaemia (TIA) and all-cause mortality at 12-month follow-up after implantation of Bridge for the treatment of symptomatic vertebral artery stenosis in subjects who had been taking different durations of dual-antiplatelet therapy (3 vs 6 months) and ticagrelor monotherapy.",[80,81],"Brain Disease","Vertebral Artery Stenosis","2024-03-04",{"date":84,"type":40},"2024-03-08",{"date":86,"type":40},"2023-12-05",{"date":88,"type":21},"2026-06-30",{"name":46,"class":47},""]